Now Enrolling!
Essential Oil Allergy Testing

Our team is conducting a study on allergy diagnostic testing. If you have a suspected allergy to tea tree essential oil (Melaleuca alternifolia) you may be a good fit for this project.

Now Accepting New Participants

What's Involved?

  • attend a brief orientation
  • visit a participating clinic 3 times in 5 days; visits last 15-20 minutes each

Who Can Join?

  • healthy adults, any age
  • suspected allergy to tea tree essential oil
  • resident of the United States

Will I Be Paid?

Yes! You will receive FREE patch testing with follow-up. You will also receive up to $75 compensation for completing the study ($25 per visit).

Learn More

Getting Started

To get started, complete the initial screening survey, which can be found here. A researcher will review your health history to ensure the study is a good fit for you.

If you are invited to participate, you will receive a link to schedule a 5-10 minute orientation meeting with a member of our team. During this time we will answer any questions you may have. Afterwards, you will receive your supplies, including a 60-day supply of the supplement.

During the Study

Testing will involve three visits during a one-week period. Each visit will take 15-20 minutes.

You'll visit the clinic on Monday to have the patches applied, on Wednesday to have them removed, and again on Friday to have them evaluated.

Your Benefits

We will send you up to $75 in a Visa/Mastercard cash card, or an e-gift card at over 100 popular online retailers. You will receive $25 per site visit completed.

During the study, our team is available to you 24/7.

Interested in the results?  Once the study is complete, a private zoom invitation will be sent to all study participants with an overview of the findings!

Important Info

The purpose of this study is to evaluate the rate of tea tree essential oil dermal reactions. This clinical trial protocol has been evaluated and approved by an independent third-party ethical review board which is accredited by the US Department of Health and Human Services' Office of Human Research Protections (HHS-OHRP). It is conducted in compliance with the Declaration of Helsinki, the Belmont Report, the regulations outlined in 45 CFR 46, and ICH GCP E6 (R2). The protocol is also registered in a World Health Organization (WHO) approved clinical trial registry.